Stockscreener 앱 받기
64.39
3.27%
2.04
시간 외 거래:
64.55
0.16
+0.25%
전일 마감가:
$62.35
열려 있는:
$63.45
하루 거래량:
122.87K
Relative Volume:
0.69
시가총액:
$431.35M
수익:
-
순이익/손실:
$-14.99M
주가수익비율:
-31.16
EPS:
-2.0665
순현금흐름:
$-10.01M
1주 성능:
+8.36%
1개월 성능:
+8.64%
6개월 성능:
-4.89%
1년 성능:
+88.83%
1일 변동 폭
$62.98
$66.61
1주일 범위
$58.01
$66.61
52주 변동 폭
$29.18
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
64.39 | 411.79M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Morgan Stanley | Overweight |
| 2025-11-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 개시 | Leerink Partners | Outperform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-09-09 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-08-26 | 재개 | H.C. Wainwright | Buy |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
모두보기
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade - Zacks Investment Research
Monopar Therapeutics Q1 2026 Earnings: Smaller-than-Expected Loss as EPS Surprises PositivelyRevenue Report - newsline.com
Understanding Momentum Shifts in (MNPR) - Stock Traders Daily
Monopar Therapeutics (MNPR) Climbs Nearly 2%, Approaches Key Resistance at $63.64Inside Day Breakout - newsline.com
Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $101 - Moomoo
Monopar Therapeutics stock declines as late-session selling erases earlier gains - Traders Union
Monopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained - TipRanks
Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail
A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $101 to $105 - Moomoo
MNPR Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineFinal Results - newsline.com
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics (MNPR) Showcases Promising Phase 2 Results at EASL Congress 2026 - GuruFocus
Monopar presents phase 2 data on Wilson disease treatment - Investing.com UK
Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 - GlobeNewswire Inc.
Monopar Therapeutics Presents Phase 2 Results of ALXN1840 (Tiomolibdate Choline) for Wilson Disease at EASL International Liver Congress 2026 7 - Minichart
MNPR Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises on Positive SurpriseEarnings Recovery Stocks - newsline.com
MNPR Q1 2026 Earnings: Narrower-than-expected loss as early-stage biotech advances radiopharmaceutical pipelineRevenue Report - newsline.com
Avoiding Lag: Real-Time Signals in (MNPR) Movement - Stock Traders Daily
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease - TipRanks
Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan
Monopar Therapeutics shares dip amid rising selling pressure - Traders Union
Monopar Therapeutics (MNPR) Holds Steady at $64.43: Slight Decline Signals ConsolidationLast Point Resistance - The Legal Advocate
What triggered Monopar Therapeutics shares' latest price surge - Traders Union
Monopar Therapeutics stock rises as short-term exhaustion signals surface after recent rally - Traders Union
Why is Monopar Therapeutics stock up today? - Traders Union
What triggered Monopar Therapeutics shares' latest price pullback - Traders Union
Monopar Therapeutics (MNPR) News Today: Latest Market and Industry Updates - Traders Union
Monopar Therapeutics stock price forecast: Holding $60.25 support as MNPR declines 2.47% - Traders Union
Monopar Therapeutics Q1 2026 Earnings: Narrower Loss Surprises MarketEarnings Outlook Update - Newser
MNPR Q1 2026 Earnings: Surprise EPS Beat in Pre-Revenue BiotechRevenue Inflection Point - The Legal Advocate
Monopar Therapeutics Presents Positive Phase 2 Results for ALXN1840 in Wilson Disease Patients - Minichart
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - The Manila Times
Monopar reports positive Wilson disease trial data publication By Investing.com - Investing.com South Africa
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data - TipRanks
Monopar reports positive Wilson disease trial data publication - Investing.com India
Monopar Therapeutics Publishes Phase 2 Trial Results of ALXN1840 for Wilson Disease in Hepatology Communications - Quiver Quantitative
Monopar Therapeutics Inc Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - marketscreener.com
ALXN1840 Wilson disease trial data published by Monopar (NASDAQ: MNPR) - Stock Titan
Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Cuts Target Price to $59.27 - Moomoo
MNPR SEC FilingsMonopar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Leerink Partners Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Saturn V, Xiaoying Tian report 345,626 MNPR shares (5.20%) — MNPR - Stock Titan
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged - TipRanks
A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $104 to $130 - Moomoo
Is Monopar Therapeutics (MNPR) Undervalued After Q1 2026 EPS Bea - GuruFocus
Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Monopar Therapeutics reports Q1 2026 loss, advances ALXN1840 NDA submission for Wilson disease. - Pluang
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):